Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Hydrocodone | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Magnesium sulfate | The therapeutic efficacy of Methapyrilene can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Methapyrilene may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Mirtazapine | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Orphenadrine | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Pramipexole | Methapyrilene may increase the sedative activities of Pramipexole. |
| Ropinirole | Methapyrilene may increase the sedative activities of Ropinirole. |
| Rotigotine | Methapyrilene may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Methapyrilene. |
| Suvorexant | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Thalidomide | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Methapyrilene may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Methapyrilene. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methapyrilene. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methapyrilene. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Methapyrilene. |
| Sodium oxybate | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ethanol | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Alaproclate. |
| Amphetamine | Amphetamine may decrease the sedative activities of Methapyrilene. |
| Phentermine | Phentermine may decrease the sedative activities of Methapyrilene. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Methapyrilene. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Methapyrilene. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Methapyrilene. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Methapyrilene. |
| Mephentermine | Mephentermine may decrease the sedative activities of Methapyrilene. |
| MMDA | MMDA may decrease the sedative activities of Methapyrilene. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Methapyrilene. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Methapyrilene. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Methapyrilene. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Methapyrilene. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Methapyrilene. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Methapyrilene. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Methapyrilene. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Methapyrilene. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Methapyrilene. |
| Ritobegron | Ritobegron may decrease the sedative activities of Methapyrilene. |
| Mephedrone | Mephedrone may decrease the sedative activities of Methapyrilene. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Methapyrilene. |
| Gepefrine | Gepefrine may decrease the sedative activities of Methapyrilene. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Methapyrilene. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Methapyrilene. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Methapyrilene. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Methapyrilene. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Methapyrilene. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Methapyrilene. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Methapyrilene. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Methapyrilene. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Methapyrilene. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Methapyrilene. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Methapyrilene. |
| Pizotifen | The risk or severity of CNS depression can be increased when Methapyrilene is combined with Pizotifen. |
| Dosulepin | The risk or severity of CNS depression can be increased when Methapyrilene is combined with Dosulepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Methapyrilene. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Methapyrilene. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Methapyrilene. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Methapyrilene. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Methapyrilene. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Methapyrilene. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Methapyrilene. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Methapyrilene. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Methapyrilene. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Methapyrilene. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Methapyrilene. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Methapyrilene. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Methapyrilene. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Methapyrilene. |